BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Dec 20, 2022
Deals

Dec. 19 Quick Takes: Sanofi, Innate deepen ties with NK licensing deal

Plus: FDA hold on Entrada’s DMD treatment and updates from Atara, AZ, LianBio-Pfizer, F2G, Protillion, and more 
BioCentury | Jun 3, 2022
Deals

June 2 Quick Takes: BMS, Immatics expand partnership to allogeneic T cells

Plus Transition’s $50M A round, Centessa’s killed kidney program and updates from Centessa, Aeglea, Immunic and more
BioCentury | Aug 21, 2021
Targets & Mechanisms

Next-generation multiple sclerosis therapies look beyond B cells 

Early-stage approaches aim for more precise immune suppression, remyelination
BioCentury | Dec 21, 2020
Deals

Agios to exit oncology, reward investors via Servier deal as lead anemia program nears submission

Amid a changing cancer landscape, Agios is selling its oncology business for at least $1.8 billion, giving Servier a commercial product and a candidate in Phase III testing. The 12-year-old biotech
BioCentury | Aug 20, 2020
Regulation

Pandemic could give advantage to newly approved MS latecomer ofatumumab

Novartis’ once-monthly anti-CD20 mAb is only auto-injectable MS drug targeting B cells 
BioCentury | Aug 13, 2020
Finance

F2G raises $60.8M to get new class of antifungal to market

Venture round could carry ‘breakthrough’ antifungal to 2022-23 launch 
BioCentury | Aug 11, 2020
Product Development

Remdesivir heads for FDA review as Gilead continues to build manufacturing pipeline 

Plus data from Omeros, PTC and a call to make mAbs accessible
BioCentury | Jun 20, 2020
Deals

Clinical scorecard for COVID-19: lessons from the first wave of controlled trials

An analysis of 25 controlled trials for COVID-19
Items per page:
1 - 10 of 137